Sertoli-Leydig cell tumor of the ovary
Journal
Journal of the Formosan Medical Association
Journal Volume
103
Journal Issue
5
Pages
388-391
Date Issued
2004
Author(s)
Abstract
Sertoli-Leydig cell tumors of the ovary are rare diseases that occur primarily in young women. The majority of these tumors are unilaterally localized, and conservative surgery is sufficient. However, these tumors exhibit a variety of histological patterns, which are significant prognostic factors. To date, no standard therapy exists. Here we report 4 cases of Sertoli-Leydig cell tumors of the ovary. One patient whose tumor was a poorly differentiated Sertoli-Leydig cell tumor with mesenchymal heterologous elements received adjuvant chemotherapy postoperatively but died of disease 2.5 years after surgery. The other 3 patients remained free of disease during follow-up. Conservative surgery is an appropriate treatment for young patients with Sertoli-Leydig cell tumors. Those who have poor prognostic factors may need adjuvant chemotherapy with a combination of bleomycin, etoposide and cisplatin.
SDGs
Other Subjects
antineoplastic agent; bleomycin; cisplatin; doxorubicin; etoposide; ifosfamide; mesna; paclitaxel; abdominal hysterectomy; adolescent; adult; androblastoma; article; cancer adjuvant therapy; cancer mortality; cancer regression; cancer survival; case report; echography; female; follow up; heterologous expression; histopathology; human; laboratory diagnosis; mesenchyme; outcomes research; ovary tumor; pelvis radiography; postoperative period; prognosis; salpingooophorectomy; tumor localization; adjuvant chemotherapy; androblastoma; middle aged; ovariectomy; ovary tumor; pathology; Adolescent; Adult; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Prognosis; Sertoli-Leydig Cell Tumor
Type
journal article